Paul Forster

"Businesses are struggling to hit their hiring goals and getting the right candidate is more competitive now than possibly ever before. In our analysis often the hiring process for many organisations is inefficient and outdated. During a period of rapid nation-wide recruitment, companies simply cannot afford to waste time and money on hiring the wrong people. Through our intelligent product offering, we can help companies hire the right people quicker."

"It is well understood that user permission requirements get more complex as enterprise clients get bigger, and serve users in different roles, with a complex number of permission exceptions. To save companies from building this from scratch, Cerbos’ open-source approach radically simplifies user and role permissions by abstracting away the complexity. At Crane, we’ve been blown away by how much value their early users are already getting from the system."

"When I met Kyle and Tom, the founders of Oxwash, I knew immediately they were the type of purposeful leaders I love to work with; their passion, drive and enthusiasm for sustainable laundry was infectious. Through the Collective Impact programme I get to meet the most inspiring founders and am constantly blown away by their innovative, creative and commercial approach to sustainable business. Oxwash will turn the traditional laundry sector on its head, proving yet again that purposeful business is great business."

"Our mission is to ensure all property sellers achieve the best price they can for their property."

"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."